Get started
FENNEC PHARMACEUTICALS INCFENNEC PHARMACEUTICALS INCFENNEC PHARMACEUTICALS INC

FENNEC PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

FRX chart


Full chart

FRX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪233.41 M‬ CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.06 CAD
Net income (FY)
‪−21.66 M‬ CAD
Revenue (FY)
‪28.68 M‬ CAD
Shares float
‪22.92 M‬
Beta (1Y)
1.58

Employees


Employees (FY)
29
Change (1Y)
−7 −19.44%
Revenue / Employee (1Y)
‪989.09 K‬ CAD
Net income / Employee (1Y)
‪−746.75 K‬ CAD

About Fennec Pharmaceuticals Inc.


Sector
Health Technology
CEO
Jeffrey S Hackman
Headquarters
Durham
Website
fennecpharma.com
Founded
1996
FIGI
BBG000BBWCT9
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

FRX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where FRX is featured.

See all sparks 

Frequently Asked Questions


The current price of FRX is 8.67 CAD — it has decreased by −0.71% in the past 24 hours. Watch FENNEC PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange FENNEC PHARMACEUTICALS INC stocks are traded under the ticker FRX.
FRX stock has fallen by −3.32% compared to the previous week, the month change is a 38.52% rise, over the last year FENNEC PHARMACEUTICALS INC has showed a −34.81% decrease.
We've gathered analysts' opinions on FENNEC PHARMACEUTICALS INC future price: according to them, FRX price has a max estimate of 21.38 CAD and a min estimate of 17.10 CAD. Watch FRX chart and read a more detailed FENNEC PHARMACEUTICALS INC stock forecast: see what analysts think of FENNEC PHARMACEUTICALS INC and suggest that you do with its stocks.
FRX reached its all-time high on Apr 9, 2018 with the price of 18.86 CAD, and its all-time low was 0.63 CAD and was reached on Sep 12, 2013. View more price dynamics on FRX chart.
See other stocks reaching their highest and lowest prices.
FRX stock is 3.08% volatile and has beta coefficient of 1.58. Track FENNEC PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is FENNEC PHARMACEUTICALS INC there?
Today FENNEC PHARMACEUTICALS INC has the market capitalization of ‪233.41 M‬, it has increased by 7.72% over the last week.
Yes, you can track FENNEC PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
FENNEC PHARMACEUTICALS INC is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
FRX earnings for the last quarter are −0.28 CAD per share, whereas the estimation was −0.12 CAD resulting in a −133.33% surprise. The estimated earnings for the next quarter are −0.19 CAD per share. See more details about FENNEC PHARMACEUTICALS INC earnings.
FENNEC PHARMACEUTICALS INC revenue for the last quarter amounts to ‪9.44 M‬ CAD, despite the estimated figure of ‪12.16 M‬ CAD. In the next quarter, revenue is expected to reach ‪11.62 M‬ CAD.
FRX net income for the last quarter is ‪−7.82 M‬ CAD, while the quarter before that showed ‪−7.60 M‬ CAD of net income which accounts for −2.95% change. Track more FENNEC PHARMACEUTICALS INC financial stats to get the full picture.
No, FRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 29.00 employees. See our rating of the largest employees — is FENNEC PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FENNEC PHARMACEUTICALS INC EBITDA is ‪2.07 M‬ CAD, and current EBITDA margin is −60.09%. See more stats in FENNEC PHARMACEUTICALS INC financial statements.
Like other stocks, FRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FENNEC PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FENNEC PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FENNEC PHARMACEUTICALS INC stock shows the sell signal. See more of FENNEC PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.